Posted on 1/31/18
Johnson & Johnson to Participate in the Leerink Partners 7th Annual Global Healthcare Conference
Johnson & Johnson (NYSE: JNJ) will participate in the Leerink Partners 7th Annual Global Healthcare Conference on Wednesday, Feb. 14, at Lotte New York Palace, NY. . . .
Posted on 1/31/18
Capital BlueCross Ranks Highest Among Health Insurers Nationally in American Customer Satisfaction Index for Fourth Year
Capital BlueCross today announced that, for the fourth straight year, from 2014 to 2017, it scored higher than all health insurance companies nationally that are tracked . . .
Posted on 1/31/18
Pfizer's Q4: Should Investors Buy The Dip?
Many consumers are familiar with the products of healthcare giant Pfizer (PFE), the business that is responsible for the blockbuster drug Lipitor.The company is also well-known . . .
Posted on 1/31/18
What You Should Really Examine in Pfizer's Q4 Earnings Results
When Pfizer (NYSE:PFE) reported its third-quarter results in October, the big drugmaker announced a mixture of good news, bad news, and so-so news. Although the company's . . .
Posted on 1/31/18
Celgene Looking Good With Plans for More Growth
Celgene's (NASDAQ:CELG) fourth-quarter report tends to be unsurprising because the company usually offers -- as it did this year -- preliminary revenue and earnings as well . . .
Posted on 1/30/18
What to Expect in Pfizer's Q4 Earnings Results
While the stock market roared in 2017, Pfizer (NYSE:PFE) turned in a respectable, but not spectacular, performance, with its stock gaining 11.5%. The big pharma company's . . .
Posted on 1/30/18
Amarin Announces Proposed Public Offering of American Depositary Shares
BEDMINSTER, N.J., and DUBLIN, Ireland, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced a registered underwritten public offering of its American Depositary . . .
Posted on 1/30/18
Letco Med, L.L.C. Announces Partnership with ARL Bio Pharma
Letco Medical, L.L.C., a leading supplier of quality compounding products, supplies and equipment, together with ARL Bio Pharma, a leader in compounding quality testing services, announce . . .
Posted on 1/29/18
3 Small Biotechs That Big Drugmakers Are Probably Drooling Over
2018 just might be the best time to be a small biotech -- and own shares of small biotech stocks -- than ever before. Despite a . . .
Posted on 1/29/18
Celgene: Headwinds For Otezla Could Weigh On Stock
Source: healcare.infoCelgene (CELG) delivered Q4 revenue of $3.5 billion and non-GAAP EPS of $2.00. Revenue was up 6% sequentially and 17% Y/Y. I had the following . . .
Posted on 1/29/18
5 Things Celgene's Management Just Said That You'll Want to Know
It's been a wild ride for Celgene (NASDAQ:CELG) over the past four months. A once-promising Crohn's disease drug flopped in a late-stage study. Celgene stock tanked . . .
Posted on 1/29/18
Big Biotech Is Bustling With Buyouts
It's been a busy week in biotech. On Monday, Celgene (NASDAQ:CELG) confirmed rumors it was buying Juno Therapeutics (NASDAQ:JUNO) in a deal valued at $9 billion, . . .
Posted on 1/29/18
Is Johnson & Johnson a Safe Stock to Buy?
Johnson & Johnson (NYSE:JNJ) is a healthcare giant that sells over-the-counter products, pharmaceuticals, and medical devices. Its diversification makes it a core holding for many investors, . . .
Posted on 1/29/18
3 Reasons Celgene's Investors Should Applaud the Juno Therapeutics Buyout
In case you missed it, it turns out the rumor was true. Biotech giant Celgene (NASDAQ:CELG)recently announced that it had agreed to acquired Juno Therapeutics (NASDAQ:JUNO) . . .
Posted on 1/29/18
Better Buy: Intrexon Corporation vs. Celgene
Two very different companies are hoping to make their mark in cell therapy. Intrexon Corporation (NYSE:XON) formed its Precigen subsidiary last year to develop gene and . . .
Posted on 1/29/18
Insmed Closes Public Offering
BRIDGEWATER, N.J., Jan. 26, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM) announced the closing today of its previously announced public offering of its 1.75% convertible senior . . .
Posted on 1/26/18
Price Decline Makes Johnson & Johnson Even More Attractive
Johnson & Johnson (JNJ) reported fourth quarter and full-year 2017 earnings prior to the opening bell on 1/23/2018. Shares dropped 4.25% after earnings were released. Over . . .
Posted on 1/26/18
Johnson & Johnson Down Small on Huge Loss -- What Gives?
On this episode of the Market Foolery podcast, Chris Hill chats with Jim Mueller from Stock Advisor and Motley Fool Options and Abi Malin of Hidden . . .
Posted on 1/26/18
Strongbridge Biopharma Prices Public Offering of Ordinary Shares
DUBLIN, Ireland and TREVOSE, Pa., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP) announced that it has priced its previously announced underwritten public offering . . .
Posted on 1/25/18
A Leading US Based Biopharmaceutical Company Signs a Deal with Zycus
PRINCETON, N.J.--(BUSINESS WIRE)--Zycus, a leading global provider of a comprehensive and end-to-end Source-to-Pay suite has today announced that it has signed a deal with the leading . . .
Posted on 1/25/18
ZelisĀ® Healthcare Named as Finalist in 2018 Stevie Awards for Sales & Customer Service
BEDMINSTER, N.J.--(BUSINESS WIRE)--Zelis Healthcare, a market-leading provider of integrated healthcare cost management and payments solutions, is pleased to announce that it was named a Finalist in . . .
Posted on 1/25/18
Johnson & Johnson: Dividend King And Dividend Growth, Buy The Dip, 20% Upside Potential
Johnson & Johnson Has increased its dividend for 55 years in a row (a dividend king) and presently has a yield of 2.4% which is above . . .
Posted on 1/25/18
Johnson & Johnson Backs Away From Pfizer's Consumer Health Unit
Reuters reports that Johnson & Johnson (JNJ +1%) has withdrawn from the list of potential suitors for Pfizer's (PFE +0.3%) consumer health business, leaving GlaxoSmithKline (GSK) . . .
Posted on 1/25/18
Johnson & Johnson: Expect Underwhelming Results To Continue
Despite the gains of the last year, Johnson & Johnson (JNJ) hasn't actually outperformed the market. In fact, the stock has now vastly underperformed the market . . .
Posted on 1/25/18
Johnson & Johnson: Buying On The Dip
Johnson & Johnson (NYSE: JNJ) has been a core position in my portfolio and is likely a core position in many other portfolios. Even for passive . . .

